ONT-093

CAT: 0804-HY-15134-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-15134-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ONT-093 (OC 144-093) is a potent and orally active inhibitor of P-glycoprotein pump. ONT-093 inhibits P-gp-mediated ATPase activity with an IC50 of 0.16 μM. ONT-093 can inhibit drug efflux and increase bioavailability. ONT-093 reverses cancer cells multidrug resistance to chemotherapeutic drugs. ONT-093 can be used for the researches of cancer and infection, such as colon cancer and malarial [1][2][3].
CAS Number
[216227-54-2]
Product Name Alternative
OC 144-093; OC 144093
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
P-glycoprotein
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/ont-093.html
Purity
99.21
Solubility
DMSO : 100 mg/mL (ultrasonic) |Methanol : 125 mg/mL (ultrasonic)
Smiles
CC(C)NC1=CC=C(C2=C(C3=CC=C(NC(C)C)C=C3)N=C(C4=CC=C(/C=C/COCC)C=C4)N2)C=C1
Molecular Formula
C32H38N4O
Molecular Weight
494.67
Precautions
H302, H315, H319, H335
References & Citations
[1]Newman MJ, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000 Jun 1;60 (11) :2964-72.|[2]Chi KN, et al. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23 (4) :311-5.|[3]Sanchez CP, et al. Polymorphisms within PfMDR1 alter the substrate specificity for anti-malarial drugs in Plasmodium falciparum. Mol Microbiol. 2008 Nov;70 (4) :786-98.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1

Popular Products